Welcome to our dedicated page for Vor Biopharma SEC filings (Ticker: VOR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Vor Biopharma Inc. (Vor Bio) SEC filings page on Stock Titan provides streamlined access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Nasdaq Global Select Market issuer trading under the symbol VOR, Vor Bio reports on its clinical-stage biotechnology business focused on telitacicept, a dual BAFF/APRIL fusion protein being developed for serious autoimmune diseases.
Through this page, readers can review current and historical filings such as Forms 10‑K and 10‑Q for detailed discussions of risk factors, financial condition, and the status of telitacicept clinical programs, along with Form 8‑K reports describing material events. Recent 8‑K filings have covered topics including underwritten public offerings of common stock, a private placement with institutional investors, a reverse stock split, changes to equity incentive plans, and governance updates involving Board and executive appointments.
Vor Bio also uses 8‑K filings to furnish investor presentations and clinical data updates, for example webcasts and slide decks discussing late-breaking Phase 3 results for telitacicept in Sjögren’s disease and IgA nephropathy, as well as global development plans in generalized myasthenia gravis. Other filings, such as proxy statements (DEF 14A), describe stockholder proposals related to equity plans, warrant issuances, and capital structure changes.
On Stock Titan, these documents are complemented by AI-powered summaries that highlight key points from lengthy filings, helping users quickly understand how new financings, clinical milestones, or corporate actions may affect Vor Bio’s capital structure and development strategy. Investors can also locate information related to registered offerings on Form S‑3, at‑the‑market sales programs, and other registration statements referenced in the company’s 8‑K disclosures. This page is designed to make it easier to follow the regulatory record behind VOR, from financial reporting to telitacicept’s progress through late-stage development.
Vor Biopharma (VOR) launched a primary offering of $100,000,000 of common stock, with underwriters granted a 30‑day option to purchase up to an additional $15,000,000 of shares. The company’s stock trades on Nasdaq as “VOR.” On November 7, 2025, the last reported sale price was $18.70 per share. All share figures reflect the 1‑for‑20 reverse split effected on September 18, 2025.
Vor plans to use net proceeds to advance telitacicept, including a Phase 3 trial in primary Sjögren’s disease, manufacturing and pre‑commercialization activities, and for working capital and general corporate purposes. The company and certain insiders agreed to lock‑ups (company 60 days; directors, officers and certain stockholders 90 days). Vor also agreed not to sell under its ATM program for 30 days after this offering unless the underwriters’ option is exercised in full.
Shares outstanding were 6,282,297 as of June 30, 2025. This figure provides a baseline and is separate from the amount being offered.
Vor Biopharma Inc. filed Amendment No. 1 to its Form S-3, covering the resale by selling stockholders of up to 50,999,999 shares of common stock after effectiveness. The amendment adds Rule 473(b) language for automatic effectiveness 20 days after filing.
The shares consist of up to 16,000,000 issuable upon exercise of the RemeGen Warrant and up to 34,999,999 issuable upon exercise of PIPE Warrants; all figures reflect the 1-for-20 reverse stock split effected on September 18, 2025. The company will not receive proceeds from stockholder resales; it would receive cash only upon warrant exercises at $0.002 per share, totaling approximately $102,000 if fully exercised for cash. Examples of registered resale amounts include RemeGen Co., Ltd. 16,000,000 and RA Capital Healthcare Fund, L.P. 10,000,000. Shares outstanding were 6,853,907 as of September 18, 2025.
Vor Biopharma (VOR) amended the employment agreement of Chief Development Officer Dr. Qing Zuraw, effective November 2, 2025, for a five‑month period. If she is terminated without cause, she will receive a lump-sum, pro‑rated portion of her 2025 target bonus and, if applicable, a pro‑rated portion of her 2026 target bonus. If she resigns for any reason after December 31, 2025, she will receive the same severance benefits as a without‑cause termination.
The company also announced the appointment of Dr. Jeremy Sokolove as Chief Medical Officer via a November 3, 2025 press release furnished under Regulation FD.
Vor Biopharma (VOR): RA Capital-affiliated reporting persons, identified as a director and 10% owner, reported open-market sales of common stock on October 28–30, 2025.
Disclosed transactions: 87,828 shares at a weighted average price of $27.10; 36,483 shares at $28.18; 251,518 shares at $25.22; and 24,579 shares at $25.12. After these trades, 779,652 shares were beneficially owned indirectly. Prices reflect weighted averages across multiple trades within stated ranges. The shares are held directly by RA Capital Healthcare Fund, L.P., with beneficial ownership disclaimed except to the extent of pecuniary interest.
Vor Biopharma furnished a Regulation FD update via an 8-K. On October 28, 2025, the company hosted a webcast to discuss late‑breaking 48‑week Phase 3 clinical trial data from China for telitacicept in primary Sjögren’s disease. The presentation used in the webcast was furnished as Exhibit 99.1 and is not deemed filed under the Exchange Act.
Vor Biopharma (VOR): Insider share sales reported by 10% owner/director affiliates. Entities associated with RA Capital reported open-market sales of common stock on three dates. On 10/23/2025, 76,880 shares were sold at $28.01 (weighted average). On 10/24/2025, 53,345 shares were sold at $28.01 (weighted average). On 10/27/2025, 90,941 shares were sold at $28.12 (weighted average).
After these transactions, 1,180,060 shares were beneficially owned indirectly. The filing identifies the reporting persons as RA Capital Management, L.P., RA Capital Management GP, LLC, RA Capital Healthcare Fund, L.P., and individuals including Dr. Peter Kolchinsky and Mr. Rajeev Shah, with holdings held directly by the Fund. Footnotes note weighted-average pricing across ranges and that certain parties disclaim beneficial ownership except to the extent of pecuniary interest.
Vor Biopharma (VOR) insiders affiliated with RA Capital reported open‑market sales of common stock on 10/20/2025 and 10/21/2025. Transactions included 70,366 shares at a weighted average price of $29.63 (range $29.045–$30.025), 6,553 shares at $30.12 (range $30.05–$30.26), and 25,027 shares at $28.11 (range $28.00–$28.475) held indirectly by the RA Capital Healthcare Fund. The RA Capital Nexus Fund sold 13,817 shares at $29.63 and 1,287 shares at $30.12.
Following these transactions, the Healthcare Fund beneficially owned 1,401,226 shares indirectly; the Nexus Fund held 0 shares. The filing was made by more than one reporting person. Reporting persons are noted as Director and 10% Owner and disclaim beneficial ownership except to the extent of pecuniary interest.
Vor Biopharma (VOR) director Reid Hoffman reported open‑market sales of common stock. On 10/17/2025, sales included 24,689 shares at a weighted average price of $30.2207 (executed in multiple trades ranging from $30.00–$30.88) and a separate trade of 1,028 shares at $31.00. Additional sales were 11,616 shares on 10/20/2025 at a weighted average price of $30.0535 (range $30.00–$30.27) and 200 shares on 10/21/2025 at $30.075.
Following these transactions, the filing reports 1,166,909 shares beneficially owned. The securities are held by Reprogrammed Interchange LLC; Mr. Hoffman may be deemed a beneficial owner by virtue of shared control and indirect pecuniary interest and disclaims beneficial ownership except to the extent of his pecuniary interest.
Vor Biopharma (VOR): Form 4 insider sales reported. A reporting group including Reprogrammed Interchange LLC sold a total of 73,676 shares of Vor Biopharma common stock on 10/15/2025 and 10/16/2025. The transactions were executed at weighted average prices of $31.0496, $32.0459, $32.7733, and $30.4548.
Following these sales, 1,204,442 shares were beneficially owned as reported after the final transaction. The securities are held by Reprogrammed Interchange LLC; per the disclosure, Reid Hoffman may be deemed a beneficial owner through shared control and indirect pecuniary interest, and he disclaims beneficial ownership except to the extent of his pecuniary interest. Each sale was executed in multiple trades within disclosed price ranges.
Vor Biopharma (VOR) disclosed insider sales by affiliates of RA Capital on multiple dates. The filing lists open-market sales (Code S) on 10/15/2025, 10/16/2025, and 10/17/2025 at weighted average prices within disclosed ranges. Examples include sales at $30.55 and $31.17 on 10/15, at $29.32 and $30.36 on 10/16, and at $29.12, $30.28, and $31.00 on 10/17.
Following the reported transactions, the table shows beneficially owned amounts of 1,503,172 shares for the Fund and 15,104 shares for the Nexus Fund, each reported as indirectly held. The report notes the issuer’s 1-for-20 reverse stock split on September 18, 2025, and that the reporting persons are identified as a Director and 10% Owner.
FAQ
What is the current stock price of Vor Biopharma (VOR)?
What is the market cap of Vor Biopharma (VOR)?
